With an AstraZeneca cancer drug in one hand, $37M in the other, Shanghai's Alpha Bio zooms into a PhII study
One of the more prominent Chinese venture firms in biotech has put some cash behind yet another Chinese start-up looking to develop a Big Pharma drug for the booming Asian market.
In what has fast become a routine event, Qiming Venture Partners led a $37 million Series A tranche for Shanghai-based Alpha Biopharma. Alpha Bio has plans to launch a global, multi-center Phase II clinical study of AZD3759, a TKI for EGFR mutation-positive cases of non-small cell lung cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.